CWBR CohBar is a clinical stage biotechnology company which develops mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases.
CWBR closed few months ago a $15.0 Million Offering of Common Stock and Warrants at $0.72, so this is a safe upside in my opinion if you want to enter now.
Cantor Fitzgerald brokerage has a $2.5 price target for it.
Trade active
CWBR Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.